je.st
news
Alnylam Pharmaceuticals Keeping Multiple High-Potential Programs Moving Forward
2015-11-14 12:16:55| Biotech - Topix.net
Alnylam has had a summer of discontent as worries about the efficacy and tolerability of a lead drug combine with broader concerns about drug pricing and biotech valuations. Even if revusiran is inferior to Isis's rival compound, a backup compound could more than make up the difference and Alnylam is making broad overall progress with its pipeline.
Tags: multiple
forward
programs
moving
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||